Across TCGA pan-cancer cohorts, MAML2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAML2 data layer compared with 27 for mass-spec protein and 14 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAML2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAML2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where MAML2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.775	0.414	.001	72	view →
UCEC	DFS	Median	III,IV	1.000	0.466	.009	26	view →
LSCC	DFS	Quartile	II,III,IV	0.859	1.000	.007	9	view →
LUAD	DFS	Median	III,IV	0.572	0.910	.005	3	view →
HNSC	DFS	Tertile	III,IV	0.855	0.576	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MAML2 tumor-vs-normal RNA expression · all MAML2 data types